A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.
A research team at KAIST has developed GB2Ab, a therapeutic antibody candidate that blocks signals responsible for appetite suppression, weight loss, and muscle wasting in cancer cachexia. The antibody successfully reversed weight and muscle loss in mouse models.
The Phase 2 BESTOW clinical trial demonstrated that tegoprubart, a novel anti-CD40L antibody therapy, was superior to tacrolimus, the current standard of care, at preserving kidney function in adults receiving their first kidney transplant. The trial results suggest a potential advancement in immunosuppressive treatment regimens for transplant patients.
Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.
Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.
Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.
Revolution Medicines' breakthrough pill targeting KRAS mutations in advanced pancreatic cancer received FDA approval, priced at over $475,000 per year. The drug nearly doubles survival in patients with this hard-to-treat cancer.
Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.
The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.